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The previous version of the expert position 
statement of the Polish Cardiac Society Working 
Group on Cardiovascular Pharmacotherapy (SFSN 
PTK) on the management of dyslipidemia in Poland 
was published 4 years ago [1]. The first edition of this 
document has been celebrating its 8 birthday [2]. 
This initiative is an aftermath of the expert 
discussion during the SFSN PTK Winter Meeting 
in Sopot.
Similarly, to the first two editions, the present 
document includes 10 conclusions that have often 
been referenced to during debates, meetings, and 
symposia on the management of lipid disorders and 
prevention of cardiovascular disease.
The popularity of both previous editions, 
which has surpassed the authors’ expectations, and 
major achievements of the recent years warrant 
an attempt to update the previous expert posi-
tion statement in the present document to make 
it consistent with the present reality of treating 
dyslipidemia in Poland. The traditional name of the 
“Declaration of Sopot” has been retained.
1. Dyslipidemia is the most common risk 
factor for cardiovascular disease in Poland. 
Despite advances in drug therapy, health promotion 
initiatives, and continuous physician and patient 
education efforts, epidemiological data indicate 
no significant improvement in the overall situa-
tion in Poland in the recent years. Most recent 
epidemiological analyzes from the WOBASZ and 
WOBASZ II studies indicate that in 2013–2014 
(WOBASZ II study), hypercholesterolemia was 
present in 70.3% of men and 64.3% of women in 
a representative sample of adult Poles [3]. Isolated 
low high-density lipoprotein cholesterol (HDL-C) 
level was noted in 5.1% of men and 7.3% of women, 
and isolated hypertriglyceridemia was found in 
5.6% of men and 2.4% of women. These rates 
have not changed significantly since 2003–2005 
(WOBASZ study). Of note, only 39.4% of subjects 
with hypercholesterolemia were unaware of their 
condition, 17% were aware but not treated, 15% 
received ineffective treatment, and only 6% were 
aware and treated to target lipid levels.
These data are even more important due to 
the fact that European studies in patients with 
established coronary heart disease, such as the 
EUROASPIRE-IV study, show that low-density 
lipoprotein cholesterol (LDL-C) level is elevated 
in more than 80% of these patients, and despite 
wide use of statins, only 19.3% of patients reach 
target lipid levels [4, 5].
At the same time, studies on the effect of 
cardiovascular risk factor modification over the 
last two decades indicate that the increase in the 
mean length of life in Poland has been mostly re-
lated to a reduction in mortality due to coronary 
heart disease [6]. Using the IMPACT model, it was 
shown that a reduction in the mean cholesterol 
level in the Polish population that was seen in the 
last decades accounted for 39% of the reduction 
in coronary artery disease mortality [6]. These 
findings highlight the need for wide-ranging efforts 
to reduce cholesterol levels at the individual and 
population level.
2. Low detection rate of lipid disorders is 
one reason for ineffective treatment. 
Currently, routine lipid level testing is recom-
mended in all men above 40 years of age and in all 
women who are postmenopausal or above 50 years 
of age [7]. Such late testing for plasma cholesterol 
level, without including it in periodic health check 
or occupational medicine testing panels, may re-
duce the opportunity for early detection of severe 
hypercholesterolemia. The following clinical condi-
tions may predispose for earlier testing:
 — established cardiovascular disease;




 — moderate or severe chronic kidney disease;
 — high, very high, or extremely high cardiovas-
cular risk;
 — autoimmune inflammatory diseases (such as 
rheumatoid arthritis, systemic lupus erythe-
matosus, or psoriasis);
 — gestational diabetes;
 — hypertension in pregnancy;
 — clinical manifestations of dyslipidemia (such 
as tendon xanthomas, xanthelasma, or corneal 
lipid degeneration [corneal arcus]);
 — family history of lipid disorders or premature 
cardiovascular disease;
 — antiretroviral treatment.
In all cases, testing should include direct 
total cholesterol (TC), HDL-C and triglyceride 
level measurements and calculation of LDL-C 
(using the Friedewald formula) and non-HDL 
cholesterol (non-HDL-C) levels. In case of hyper-
triglyceridemia (> 400 mg/dL [> 4.5 mmol/L]), 
direct LDL-C level measurement is necessary. It 
is not justified to measure single lipid fractions 
without evaluation of the full lipid profile, and ad-
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ditional measurements of apolipoprotein B (apoB), 
apolipoprotein A (apoA), and lipoprotein a [Lp(a)] 
levels and determinations of the apoB to apoA ratio 
and the non-HDL-C to HDL-C ratio may be con-
sidered in selected clinical settings. Traditionally, 
lipid levels are measured in fasting conditions but 
studies indicate that measurements of most lipid 
parameters yield similar values in postprandial and 
fasting conditions. The exception is triglyceride 
level which shows a postprandial increase by about 
30 mg/dL (0.3 mmol/L) [8].
In addition, for more precise categorisation 
of lipid disorders in selected patients at high car-
diovascular, the European guidelines recommend 
Lp(a) level measurement in subjects with:
 — premature cardiovascular disease;
 — familial hypercholesterolemia;
 — family history of premature cardiovascular 
disease and/or increased Lp(a) level;
 — recurrent cardiovascular events despite opti-
mal lipid-lowering therapy;
 — Pol-SCORE 10-year cardiovascular mortality 
risk ≥ 5%.
Following initiation of lipid-lowering therapy, 
lipid levels should be evaluated every 8 ± 4 
weeks to adjust therapy until target lipid levels are 
reached. In patients with adequate on-treatment 
lipid levels, annual lipid profile testing is recom-
mended. In addition, creatine kinase (CK) and 
alanine aminotransferase (ALT) levels should be 
evaluated prior to the initiation of lipid-lowering 
therapy. Single ALT level retesting is indicated at 
8–12 weeks after lipid-lowering therapy initiation 
or dose escalation. Further routine CK and ALT 
level retesting is not necessary unless prompted 
by clinical symptoms [9].
3. Lipid disorder nomenclature needs to 
be unified. A common problem is misuse of the 
term “hypercholesterolemia” to describe any form 
of lipid disorders. Use of proper nomenclature in 
the medical records is of particular importance 
as specific diagnoses imply not only the type of 
recommended therapy but also non-drug treat-
ment. Definitions of specific lipid disorders are 
given below:
 — dyslipidemia — abnormal plasma level of 
any lipid and/or lipoprotein fraction; this term 
encompasses all definitions given below;
 — hypercholesterolemia — plasma TC level 
≥ 190 mg/dL (≥ 5.0 mmol/L) or LDL-C level 
above the recommended values in a given 
cardiovascular risk category (see below);
 — atherogenic dyslipidemia — plasma triglyc-
eride level ≥ 150 mg/dL (≥ 1.7 mmol/L), low 
HDL-C level (< 40 mg/dL [< 1 mmol/L] in 
men; < 48 mg/dL [< 1.2 mmol/L] in women), 
and the presence of abnormal LDL particles 
(so called small dense LDL) in plasma. LDL-C 
level may be normal or elevated; the latter 
condition is called mixed atherogenic dys-
lipidemia. Atherogenic dyslipidemia is an 
important factor contributing to the residual 
risk of macroangiopathic lesions;
 — hypertriglyceridemia — plasma triglyc-
eride level > 150 mg/dL (> 1.7 mmol/L) 
with normal LDL-C level; severe hypertri-
glyceridemia — plasma triglyceride level 
≥ 800 mg/dL (≥ 9 mmol/L).
4. Screening for hereditary lipid disorders 
may improve the epidemiological situation in 
Poland. The most common inheritance patterns of 
lipid disorders include such conditions as:
 — polygenic hypercholesterolemia — de-
termined by the presence of multiple genetic 
polymorphisms combined with inadequate diet 
(incidence 1 per 10–20);
 — familial hypercholesterolemia (FH) — 
may be either homozygous (incidence 1 per 
160,000–1,000,000) or heterozygous (inci-
dence 1 per 200–500);
 — familial combined hyperlipidemia — inci-
dence 1 per 100–200;
 — familial dysbetalipoproteinemia — incidence 
1 per 5000;
 — familial lipoprotein lipase deficiency — inci-
dence 1 per million;
 — analphalipoproteinemia — incidence 1 per 
million;
 — familial lecithin cholesterol acyltransferase 
deficiency (LCAT) — incidence 1 per million.
Due to a high rate and specific treatment 
approach, a particularly challenging problem in 
clinical practice is heterozygous familial hypercho-
lesterolemia (HeFH). It has been estimated that 
HeFH may be present in about 150,000 people in 
Poland [10]. The risk of coronary heart disease 
in subjects with definite or probable HeFH is 
increased at least 10-fold. Abnormal function of 
three genes has been identified so far as the cause 
of HeFH:
 — LDL receptor gene (the most common cause);
 — apoB gene;
 — proprotein convertase subtilisin/kexin type 9 
(PCSK9) gene.
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The genetic defect is unknown in some pa-
tients.
It has been estimated that if patients with FH 
are not treated, premature atherosclerotic disease 
develops in about 25% of women and about 50% of 
men in this population [11]. Long-term intensive 
lipid-lowering therapy may significantly reduce 
this risk. Due to high costs and low availability 
of genetic tests, it is recommended that testing 
for HeFH should be undertaken only in subjects 
fulfilling any of the following criteria:
 — serum TC level ≥ 310 mg/dL (≥ 8 mmol/L) in 
an adult patient or a family member;
 — premature coronary heart disease in patient 
or a family member;
 — tendon xanthomas in patient or a family mem-
ber;
 — sudden cardiac death at a young age in a fam-
ily member.
The most effective approach to the identifica-
tion of new FH cases is cascade testing in the rela-
tives of a proband identified based on TC or LDL-C 
level or the presence of a mutation confirmed by 
genetic testing (if performed). According to the 
current recommendations, genetic testing may 
facilitate and accelerate the diagnosis but is not 
required for that purpose. It also cannot be a prereq-
uisite for therapeutic programs or reimbursement 
as this would limit the availability of contemporary 
therapies. The condition may be reliably diagnosed 
based on the Dutch Lipid Clinic Network-WHO and 
the Simon Broome Register criteria (Table 1) [12].
Following the diagnosis, lipid-lowering therapy 
should be promptly initiated, preferably in a spe-
cialised centre [12].
5. Cardiovascular risk evaluation is the 
basis for lipid-lowering therapy. A comprehen-
Table 1. Diagnostic criteria for familial hypercholesterolemia — scoring system (adapted from  
The Dutch Lipid Clinic Network-WHO and the Simon Broome Register) [12].
Criteria Points
Clinical history
Patient with premature coronary artery disease (men < 55 years, women < 60 years) 2
Patient with premature cerebral or peripheral vascular disease (men < 55 years, women < 60 years) 1
Family history
First-degree relative with known premature coronary artery disease (men < 55 years, women  
< 60 years) OR
1
First-degree relative with known LDL-C level > 95th percentile for age and sex in a given country  
(> 190 mg/dL [> 4.9 mmol/L])
1
First-degree relative with tendinous xanthomata and/or corneal arcus OR 2
Children and adolescents aged less than 18 years with LDL-C level > 95th percentile for age and  






LDL-C > 325 mg/dL (> 8.5 mmol/L) 8
LDL-C 251–325 mg/dL (6.5–8.4 mmol/L) 5
LDL-C 191–250 mg/dL (5.0–6.4 mmol/L) 3
LDL-C 155–190 mg/dL (4.0–4.9 mmol/L) 1
Genetic tests
Confirmed mutation in the LDL receptor, apoB or PCSK9 gene 8





apoB — apolipoprotein B; LDL-C — low-density lipoprotein cholesterol; LDLR — low-density lipoprotein receptor; PCSK9 — proprotein  
convertase subtilisin/kexin type 9
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sive evaluation of patient health status including 
classical and non-classical cardiovascular risk fac-
tors is necessary to plan lipid-lowering therapy. 
According to the primary prevention guidelines, 
risk evaluation should be based on the SCORE risk 
estimation system adapted for the Polish popula-
tion (Pol-SCORE) but should also include additional 
risk factors that are not routinely taken into account 
[13]. Determination of the risk category may be 
guided by Table 2 based on the Pol-SCORE risk 
estimation system. Recent findings of PCSK9 in-
hibitor trials indicate that very low achieved LDL-C 
levels are associated with improved outcomes, 
a reduced risk of cardiovascular events, and re-
gression of atherosclerotic lesions in the vascular 
system [14, 15]. In the present document, we in-
troduced a new postulated category of extremely 
high cardiovascular risk that is based in part on the 
recommendations of American endocrinological 
societies [14]. The risk classification recommended 
by this expert consensus panel is the first such tool 
in currently available documents (Table 2).
By suggesting the above target LDL-C levels, 
which have not been proposed until now in other 
documents, this expert consensus panel has also 
been the first to make a distinction between low 
and moderate risk patients regarding target LDL-
C levels. In high risk patients, target LDL-C level 
below 70 mg/dL (< 1.8 mmol/L) was suggested, 
with target LDL-C level below 55 mg/dL (< 1.4 
mmol/L) in very high risk patients (benefits from 
achieving such goal compared to the traditional 
target of 70 mg/dL [< 1.8 mmol/L] were prospec-
tively shown, e.g., in the IMPROVE-IT study), and 
target LDL-C level < 35 mg/dL (< 0.9 mmol/L) 
was suggested for selected subjects at extremely 
Table 2. Target low-density lipoprotein levels in relation to the cardiovascular risk profile  
(authors’ original contribution).
Risk category Presence of disease, risk factors  
or 10-year Pol-SCORE risk
Target LDL-C level
Extremely high Multiple previous cardiovascular events and/or  
revascularization procedures
< 35 mg/dL (< 0.9 mmol/L)
Stenting for left main coronary artery disease and/or  
multivessel coronary artery disease (complex percutaneous 
coronary intervention due to multivessel coronary  
artery disease)
Generalized atherosclerosis — involving multiple vascular 
beds with additional risk factors
Progression of atherosclerotic cardiovascular disease  
despite achieving and maintaining LDL-C level  
< 55 mg/dL (< 1.4 mmol/L)
Very high Progression of atherosclerotic cardiovascular disease  
despite achieving and maintaining LDL-C level  
< 70 mg/dL (< 1.8 mmol/L)
< 55 mg/dL (< 1.4 mmol/L)
Acute coronary syndrome, established coronary,  
carotid, or peripheral arterial disease
Previous revascularization
Pol-SCORE risk > 20%
Diabetes or stage 3–4 chronic kidney disease with  
one or more risk factors
Familial hypercholesterolemia
History of premature atherosclerotic cardiovascular  
disease (< 55 years in men, < 65 years in women)
Established cardiovascular disease in patients with  
diabetes or stage 3–4 chronic kidney disease
High ≥ 2 risk factors and Pol-SCORE risk 10–20%
Diabetes or stage 3–4 chronic kidney disease  
without other risk factors
< 70 mg/dL (< 1.8 mmol/L)
Moderate < 2 risk factors and Pol-SCORE risk < 10% < 100 mg/dL (< 2.6 mmol/L)
Low No additional risk factors < 115 mg/dL (< 3.0 mmol/L)
LDL-C — low-density lipoprotein cholesterol; SCORE — Systematic COronary Risk Evaluation
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high risk, based on prospective PCSK9 inhibitor 
trials that showed cardiovascular benefits with 
this drugs in secondary prevention (evolocumab in 
the FOURIER study, alirocumab in the ODYSSEY 
OUTCOMES study).
The secondary therapeutic goal is non-HDL-C 
level calculated as TC level minus HDL-C level. 
This goal includes LDL-C, very low density lipo-
protein (VLDL) cholesterol, and cholesterol in 
partially catabolized VLDL (so called remnants). 
Evaluation of non-HDL-C is warranted in particular 
in patients with hypertriglyceridemia. In contrast 
to target LDL-C levels, there are currently no data 
to suggest that a different target non-HDL-C level 
classification should be introduced compared to 
that suggested in the 2016 European guidelines [7]. 
However, by adapting the above target LDL-C level 
classification for non-HDL-C levels, the following 
values could be proposed:
 — extremely high risk: < 65 mg/dL (< 1.7 mmol/L);
 — very high risk: < 85 mg/dL (< 2.2 mmol/L);
 — high risk: < 100 mg/dL (< 2.6 mmol/L);
 — moderate risk: < 130 mg/dL (< 3.4 mmol/L);
 — low risk: < 145 mg/dL (< 3.8 mmol/L).
Regarding the remaining lipid fractions, levels 
associated with a reduced cardiovascular risk but 
not constituting therapeutic goals themselves 
should be defined in accordance with the Euro-
pean guidelines. The values given below should 
be considered additional prognostic factors but not 
therapeutic goals.
 — triglyceride level < 150 mg/dL (< 1.7 mmol/L);
 — HDL-C level > 40 mg/dL (> 1.0 mmol/L) 
in men and > 48 mg/dL (> 1.2 mmol/L) in 
women.
These restrictive recommendations, proposed 
for the first time in the Third Declaration of Sopot, 
are consistent with the current medical knowledge 
and achievable using contemporary drug therapies.
6. It is necessary to introduce standardised 
laboratory report forms. As already mentioned, 
only maximum acceptable LDL-C levels were given 
for all patient groups regardless of baseline cardio-
vascular risk, with no reference to the lower limit of 
acceptable values. This is related to the fact that data 
from PCSK9 inhibitor trials that evaluated these most 
potent available lipid-lowering drugs were not previ-
ously known, and these data indicate that achieving 
even very low LDL-C levels may be safe for patients. 
An analysis of patients who achieved LDL-C levels 
below 25 mg/dL (0.6 mmol/L) or below 15 mg/dL 
(0.4 mmol/L) during treatment with PCSK9 
inhibitors showed that even with these values, no 
increased risk of adverse drug effects or adverse 
events related to neurocognitive disturbances is 
observed [15].
On the other hand, many practitioners still be-
lieve that very low cholesterol levels pose a health 
risk for the patient and call for a reduction of the 
intensity of lipid-lowering therapy. These concerns 
are exaggerated by the fact that some laboratories 
mark low values as abnormal, using ranges of ac-
ceptable values. In some cases, this approach may 
prompt patients to discontinue treatment, leading 
to worse outcomes.
For that reason, this expert consensus panel 
suggests a recommendation to standardize labora-
tory report forms so as they indicate target ranges 
in accordance with the most recent recommenda-
tions and medical knowledge and do not generate 
a risk of potential errors by patients or physicians. 
A proposal of such a form is shown in Figure 1.
7. It is necessary to recommend lifestyle 
modifications in all patients. The goal is to 
achieve target lipid levels and improve patient 
compliance.
A change in nutrition is the basic approach that 
allows reducing LDL-C level. However, a healthy 
diet does not only reduce lipid levels but also has 
a beneficial effect on other cardiovascular risk factors 
beyond LDL-C level. Nutrition has a role mostly in 
the prevention and treatment of mild and moderate 
hypercholesterolemia in primary prevention, and 
of atherogenic dyslipidemia, particularly by its 
effect on triglycerides, small dense LDL, and low 
HDL-C levels which are associated with obesity 
and insulin resistance.
Taking into account problems related to treat-
ment safety and the risk of adverse effects that 
may result from drug treatment in some patients, 
in all cases it is strongly recommended to initiate 
non-drug therapy with an appropriate diet which 
beneficially modulates lipid profile without a risk of 
adverse effects. The major components of the di-
etary approach include reduction of total fat intake 
to 25–35% of the overall energy intake, saturated 
fat intake to 7% of the overall energy intake, and 
cholesterol intake to < 200 mg daily [16]. In par-
ticular, saturated fatty acids are a nutritional factor 
that has the strongest effect on LDL-C level. It has 
been estimated that per each additional 1% of en-
ergy intake from saturated fat, serum LDL-C level 
increases by 0.8–1.6 mg/dL [17]. Dietary treatment 
of hypertriglyceridemia should include reduction of 
carbohydrate intake, in particular intake of simple 
sugars, and weight loss should be recommended 
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in obese subjects. In severe hypertriglyceridemia, 
intake of all fat should be reduced due to the pres-
ence of chylomicrons.
An important adjunct to dietary treatment and 
lifestyle modifications involving increased physical 
activity may be the use of functional foods that may 
reduce LDL-C level by as much as 10% (marga-
rines enriched with fitosterols and fitostanols). In 
addition, new products based on plant substances 
have been available for some time on the market 
that are characterized by lipid-lowering effects 
supported by evidence-based medicine data. These 
include preparations containing monacolin (natural 
lovastatin), a constituent of red yeast rice, which 
may reduce LDL-C level by 20%, and bergamot 
products from bergamot orange that originates 
from Calabria which have a beneficial effect on lipid 
profile and carbohydrate metabolism.
As in the previous Declaration of Sopot [1], we 
continue to endorse the pyramid of lipid-lowering 
therapy, with physical activity and lifestyle modifi-
cations being the mainstay of lipid profile modifica-
tion and therapeutic interventions in dyslipidemia, 
followed by treatment with potent statins and pos-
sibly combined drug treatment (Fig. 2).
Figure 1. A proposed appropriate form to report lipid profile testing results. Note: risk categories and target values 
have been proposed for the first time in the present document — see Chapter 5 of the Third Declaration of Sopot.
LIPID PROFILE
Date: .........................................  Test No: ...................................  Ordering physician: ..........................   Laboratory remarks: ....................................
PATIENT NAME: ..........................................................................
PESEL identification number: .......................................................
LIPID FRACTIONS RESULT  TARGET VALUE COMMENT
Total cholesterol (mg/dL) …  < 190
LDL cholesterol (mg/dL) … NOTE: primary therapeutic goal; target value for subjects at extremely  
high, very high, high, moderate or low risk is < 35 mg/dL, < 55 mg/dL,  
< 70 mg/dL, < 100 mg/dL, and < 115 mg/dL, respectively, and in some  
subjects it may be defined by a physician as an INDIVIDUAL TREATMENT GOAL.
HDL cholesterol (mg/dL) …  > 40 (men)
   > 48 (women)
Triglycerides (mg/dL) …  < 150
Non-HDL-cholesterol (mg/dL) … NOTE: secondary therapeutic goal; target value for subjects at extremely high,  
very high, high, moderate or low risk is < 65 mg/dL, < 85 mg/dL,  
< 100 mg/dL, < 130 mg/dL, and < 145 mg/dL, respectively
NOTE: LDL cholesterol level ≥ 190 mg/dL (≥ 5.0 mmol/L) in adults and ≥ 160 mg/dL (≥ 4.1 mmol/L) in subjects below 18 years of age may  
indicate familial hypercholesterolemia.
NOTE: The above lipid profile testing results should be consulted with the referring physician.
REFERRING PHYSICIAN: Target LDL cholesterol level has been set at: < ………
         ………………………………… 
         Physician signature and stamp
Figure 2. The pyramid of lipid-lowering interventions 
proposed in the Second Declaration of Sopot, modified 
to include new substances (authors’ original contribution).
662 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 6
8. Statins are superior and the most 
important lipid-lowering drug therapy. In accord- 
ance with the wording of previous Declarations of 
Sopot [1, 2], we continue to endorse and highlight 
the recommendation for statins as the major drugs 
used to treat hypercholesterolemia. They account 
for more than 90% of all lipid-lowering drugs pre-
scribed in Poland, and their use has been increasing 
year by year. Statins reduce hepatic cholesterol 
synthesis by competitive inhibition of 3-hydroxy-
-3-methylglutarylcoenzyme A (HMG-CoA) reduc-
tase. They are among the best studied drugs used 
for cardiovascular disease prevention, and their 
beneficial effect on cardiovascular mortality has 
been shown in multiple clinical trials. Pseudosci-
entific notions of “benign cholesterol” and “statin 
fraud” should be strongly opposed, especially that 
these views are increasingly voiced by scientific 
pseudo-authorities, aired on TV, disseminated on 
the internet, and the extent of this campaign may 
only be compared to the populism and harmfulness 
of anti-vaccination movements. We urge physi-
cian chambers, scientific societies, and national 
consultants to undertake more effective efforts to 
oppose these views which put many patients at an 
increased risk of cardiovascular adverse events 
when statin therapy is interrupted or withheld.
Of HMG-CoA reductase inhibitors used in 
Poland, rosuvastatin and atorvastatin are clearly 
characterized by the most potent lipid-lowering 
effect. Due to limitations regarding the use of 
higher simvastatin doses (in 2011, Food and Drug 
Administration [FDA] negatively opined the use 
of 80 mg simvastatin dose and combinations of the 
remaining larger doses of this drug [40 mg, 20 mg] 
with amiodarone, verapamil, and ciclosporin due to 
an increased risk of myopathy), lipid lowering treat-
ment goals may be best achieved using these two 
drugs. This is also evidenced by the prescription 
habits of Polish physicians who increasingly use 
modern drugs, such as rosuvastatin and atorvas-
tatin, and less frequently prescribe the oldest and 
weakest drug of this class, simvastatin.
The smallest recommended rosuvastatin dose, 
5–10 mg, is equivalent to 20–30 mg of atorvastatin 
and 30–40 mg of simvastatin. In terms of lipid-
lowering potency this indicates that the ratio of 
rosuvastatin versus atorvastatin doses (per milli-
gram) is closer to 1:3 than 1:2. Thus, the availability 
of 15 mg and 30 mg rosuvastatin doses increases 
the ability to switch statin therapy to this drug in 
those patients who were previously treated with 
40 mg and 80 mg of atorvastatin, respectively. These 
intermediate statin doses allow more effective 
attainment of target LDL-C levels by individualis-
ing the therapy. An increase has been recently seen 
in the prescriptions of intermediate statin doses 
by practitioners.
Atorvastatin undergoes hepatic biotransforma-
tion by the cytochrome 450 (CYP) 3A4 isoform, 
while rosuvastatin is metabolised in the liver to 
a much lesser degree, interacting with CYP2C9. 
These differences are important due to potential 
drug interactions which are very rare with rosuv-
astatin. Rosuvastatin is contraindicated in patients 
with severe renal failure and glomerular filtration 
rate (GFR) below 30 mL/min/1.73 m2.
Although a mnemonic distinction “atorvastatin 
safer in a patient with kidney disease, rosuvastatin 
safer in a patient with liver disease” (the results 
of PLANET I and PLANET II studies still await 
publication) helps with the choice of treatment in 
the clinical settings, it would not be reasonable, 
by oversimplifying this rule in practice, to refrain 
from the use of the most effective lipid-lowering 
drug available on the market (rosuvastatin) in those 
patients in whom renal function allows it (i.e., with 
the estimated GFR > 30 mL/min) [18, 19].
The major goal of the treatment of dyslipi-
demia is to lower LDL-C level. As indicated by the 
new recommendations in the present document, 
treatment goals are currently very rigorous and 
only the use of potent drugs in high doses may 
help achieve or approach these goals. If the goal 
is not reached, the dose should be increased or 
statin should be switched to a more potent one. 
The recommendations do not indicate any specific 
statin even in patients after acute coronary syn-
dromes or a percutaneous coronary intervention. 
Regarding atorvastatin and rosuvastatin, their use 
in maximal doses was shown to induce regression 
of atherosclerotic lesions in diseased coronary 
vessels (ASTEROID and SATURN studies) [20, 
21]. Although a positive trend has been observed 
in the recent years regarding the market share 
and use of more potent statins (atorvastatin 43%, 
rosuvastatin 18%), weaker statins still account for 
as much as 31% of all prescribed lipid-lowering 
drugs. When LDL-C level is at goal, it is necessary 
to pursue the secondary treatment goal of lowering 
non-HDL-C level.
9. The remaining key lipid lowering-
therapies in addition to statins are ezetimibe, 
PCSK9 inhibitors and apheresis. It should be 
noted that although statin treatment is very effec-
tive, it does not always allow achieving the goal 
lipid levels when given as monotherapy, even 
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using the most potent statins. When attempting 
to reach the target LDL-C level, an alternative 
approach to increasing the dose and choosing the 
most potent statin is to add a selective cholesterol 
absorption inhibitor, ezetimibe, to statin. Follow-
ing oral administration, ezetimibe binds to the 
intestinal brush border and selectively inhibits in-
testinal absorption of cholesterol and plant sterols, 
which results in a reduced cholesterol transport to 
the liver. In patients with hypercholesterolemia, 
ezetimibe significantly reduces TC, LDL-C, apoB, 
and triglyceride levels, and increases HDL-C 
level. The IMPROVE-IT study showed that the 
combination of ezetimibe with even one of the 
oldest statins, simvastatin, led to a much higher 
number of patients achieving the target LDL-C 
level, and resulted in a lower high-sensitivity 
C-reactive protein level compared to patients who 
received statin monotherapy [22]. In addition, 
these additional benefits of reduced inflammation 
translated to better outcomes in patients receiving 
combination treatment, with a lower risk of major 
cardiovascular events and mortality. According to 
the current European guidelines, ezetimibe is also 
recommended as an alternative drug in patients 
intolerant to statins and in patients who do not 
reach target LDL-C levels despite statin treatment.
Another treatment approach which clearly 
deserves an increasing attention is the use of 
PCSK9 inhibitors. Their target protein, PCSK9, 
in involved in the metabolism of LDL receptors 
(LDLR). An increased PCSK9 level/function re-
duces LDLR expression by promoting lysosomal 
catabolism and increases plasma LDL-C level. 
Available PCSK9 inhibitors, which are monoclo-
nal antibodies against PCSK9, reduce LDL-C 
level by about 60% regardless of the use of other 
lipid-lowering therapies [23]. Recent trials with 
PCSK9 inhibitors showed that very low LDL-C 
levels achieved with the use of these drugs are 
associated with a reduced cardiovascular event rate 
and a reduction of atherosclerotic lesions (plaque 
volume) in coronary arteries [24, 25]. Candidates 
for this treatment include patients at a very high 
total cardiovascular risk, subjects with HeFH (and 
also some subjects with homozygous FH) receiv-
ing maximum tolerated doses of first and second 
line drugs and/or treated with apheresis, and those 
intolerant to statins, in whom LDL-C levels are 
persistently high. However, despite proven ef-
fectiveness of PCSK9 inhibitors, wider use of this 
modern therapy is hampered by economic barri-
ers and lack of reimbursement. We hope that this 
problem will be solved soon and Polish patients, 
similarly to patients in other European countries, 
will have an access to this modern therapy. This is 
even more important due to the fact that PCSK9 
inhibitors exert a very potent LDL-C-lowering ef-
fect and may reduce plaque volume [26].
It should be remembered that in patients with 
atherogenic dyslipidemia, statin monotherapy does 
not fully protect from cardiovascular events. In 
these patients, the optimal therapy, particularly 
with concomitant diabetes or metabolic syndrome, 
is a combination of a statin and fenofibrate which 
helps achieve the secondary treatment goal of 
non-HDL-C level normalization [27]. If hyper-
triglyceridemia above 440 mg/dL is present, the 
initial treatment is fibrate monotherapy, which is 
also aimed at preventing acute pancreatitis.
Finally, lipoprotein apheresis also deserves 
a mention. This treatment, also known as LDL 
apheresis, is an extracorporeal procedure to re-
move LDL-C from blood. Lipoprotein apheresis 
should be considered in patients with persis-
tently high LDL-C levels despite use of maximal 
drug doses and diet to reduce plasma choles-
terol level. Apheresis is very effective but needs 
to be systematically repeated. Due to its inva-
sive nature, it is currently reserved mainly for 
patients with FH and hyperlipoproteinemia(a). 
Following introduction of PCSK9 inhibitors to 
the routine treatment of FH, lipoprotein apher-
esis will remain the treatment of choice in pa-
tients with high Lp(a) levels (> 100 mg/dL 
[> 3.6 mmol/L]), as new drugs that lower Lp(a) 
level by as much as 90% are still being evaluated 
in clinical trials.
Figure 3. Key lipid lowering-therapies in Poland; PCSK9 
— proprotein convertase subtilisin/kexin type 9.
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All the above lipid-lowering therapies — life-
style modifications, statins, ezetimibe, PCSK9 
inhibitors, and lipoprotein apheresis — may be 
shown as parts of a sailing ship that together help 
achieve the ultimate “destination” which is maxi-
mum serum LDL-C level reduction (Fig. 3).
10. With advances in medicine and drug 
therapy, it is possible to achieve a significant 
improvement of the effectiveness of dys-
lipidemia treatment in Poland. Despite this, as 
mentioned in the introduction, therapeutic goals of 
dyslipidemia treatment continue to be reached at 
an unsatisfactory rate, only slightly above 10% also 
among high-risk patients. It is thus particularly im-
portant to identify the reasons for this poor dyslipi-
daemia control in our country. The most common 
errors of statin therapy include therapeutic nihilism 
and using too low statin doses and too weak statins 
[28]. Although lipid-lowering treatment should be 
mostly continued indefinitely in patients with es-
tablished cardiovascular disease, in many of them 
the statin dose is reduced (usually after a follow-up 
testing shows that the target LDL-C level has been 
reached) or the drug is discontinued.
Recently, with advances in drug therapy, new 
therapeutic options have become available which 
may potentially improve patient compliance and 
at least partially reduce difficulties with reaching 
target lipid levels. Most notably, these include in-
termediate statin doses (rosuvastatin 15 and 30 mg) 
which allow fine tuning of the intensity of the lipid-
lowering effect and determining the optimal dose 
for a given patient, and single-pill combinations 
(SPC). The latter in particular have been a major 
breakthrough on the pharma market. Currently, the 
following SPC containing two lipid-lowering drugs 
in one tablet are available in Poland:
 — atorvastatin and ezetimibe;
 — rosuvastatin and ezetimibe.
Even more modern SPC combining lipid-
lowering and antihypertensive medications are 
also available. These combinations have been 
introduced in response to a common problem of 
concomitant hypertension and dyslipidemia in the 
general population.
Such two-component SPC include combina-
tions of:
 — rosuvastatin and valsartan;
 — rosuvastatin and amlodipine;
 — atorvastatin and amlodipine;
 — atorvastatin and perindopril (planned to be 
released).
Three-component SPC include combinations 
of:
 — atorvastatin, perindopril, and amlodipine;
 — rosuvastatin, perindopril and indapamide 
(planned to be released).
As shown by these examples, these modern 
forms of drug therapy ale already widely available 
in Poland and now it only depends on physicians to 
what extent they will be used to improve patient 
compliance, and thus help reach target lipid levels.
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